MedPath

A Clinical trial to study the effect of Siddha medicine Kirambu Chooranam in patients having Karasthamba vatham (peripheral neuritis)

Phase 2
Not yet recruiting
Conditions
Other disorders of peripheral nervous system,
Registration Number
CTRI/2020/10/028655
Lead Sponsor
Government Siddha Medical College
Brief Summary

This is a single Non randomized open clinical trial to study the safety and efficacy of Siddha trial drug Kirambu Chooranam .The trial drug is given 1-2 grams thrice a day for 48 days. Clinical trial is conducted after conducting Pre clinical toxicity study. The trial drug Kirambu Chooranam is mentioned in Siroraththina Nadana Kaandam. During the trial all the study related data will be recorded and documented. After the completion of trial all the data will be analysed statistically.

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
40
Inclusion Criteria

Both gender of Type 2 Diabetic patients who having complaints like tingling and numbness of feet and hands, burning sensation in sole of feet, heat intolerance (unilateral/ bilateral).

Exclusion Criteria

Patients with known history of hyperthyroidism/ hypothyroidism, drug induced neuropathy, nutritional deficiency neuropathy, renal caused neuropathy.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Primary outcome is mainly assessed by diabetic control level and management of numbness and burning sensation48 days
Secondary Outcome Measures
NameTimeMethod
Secondary outcome is assessed by comparing the safety parameters before and after treatment48 Days

Trial Locations

Locations (1)

Arignar Anna Government Hospital of Indian Medicine

🇮🇳

Chennai, TAMIL NADU, India

Arignar Anna Government Hospital of Indian Medicine
🇮🇳Chennai, TAMIL NADU, India
Dr Parwin L
Principal investigator
7708756461
parwin1995@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.